New drug trial offers hope for rare blood disorder patients
NCT ID NCT03205995
Summary
This study tested whether the drug OMS721 (narsoplimab) could safely treat atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder that can damage kidneys. The trial enrolled adults and adolescents with aHUS who either didn't respond well to standard plasma treatments or needed regular plasma therapy to stay stable. Researchers primarily measured changes in platelet counts over 26 weeks to see if the drug helped control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Omeros Investigational Site
Chicago, Illinois, 60643, United States
-
Omeros Investigational Site
Vilnius, Lithuania
-
Omeros Investigational Site
Lodz, Poland
-
Omeros Investigational Site
New Taipei City, Taiwan
Conditions
Explore the condition pages connected to this study.